Improving Health in Midlife Women During Menopause Transition with Medications and Lifestyle Support

What this Trial Is About

Researchers are evaluating a range of health interventions for midlife women aged 45 to 55 who are in the late menopausal transition. This study aims to reduce menopause-related inflammation, improve heart and metabolic health, reverse biological aging markers, and lessen menopausal symptoms. The goal is to help these women lower their risk of future diseases, enhance quality of life, and increase their healthspan and productivity. Participants will be assigned to different groups based on their health risks and symptoms. One group receives preventative health advice and wears a device to monitor activity and sleep. Other groups receive medications to lower heart disease risk, improve insulin resistance, support weight loss, or reduce hot flashes with hormone therapy or non-hormonal drugs like neurokinin receptor antagonists. Treatments include drugs such as metformin, semaglutide, antihypertensives, statins, hormonal therapy, and Fezolinetant. Advice on lifestyle factors like diet, physical activity, and alcohol intake is also provided. During the study, participants undergo assessments including epigenetic aging measurements up to two years, blood tests for inflammatory markers, surveys on menopausal quality of life, and monitoring of blood vessel health. Researchers track adherence through electronic data collection and telehealth visits. Safety and symptom improvements are followed for up to two years to evaluate the impact of these interventions on womens health during menopause.

Focusing on the Menopausal Transition to Improve Mid-Life Women's Health